Recent Updates
Recently added Catalysts

BION-1301

Phase 1

Healthy Volunteer | Small molecule | Other |Novartis AG|Last Updated: Jan 10, 2023

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment36
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT05508204Open-label Safety and PK Study of BION-1301 in Japanese Healthy SubjectsPHASE1 COMPLETED 36Jul 1, 2022Dec 1, 2022Jan 10, 2023 -
Unlock Drug Trial Details
Study Design & Arms
Interventions
NameTypeDescription
BION-1301DRUGA solution for SC injection administered as a single dose
Unlock Study Design Details